Skip to content

Effect of remimazolam besylate on postoperative recovery quality after thoracoscopic lung cancer surgery: a randomized controlled study comparing with propofol

Effect of remimazolam besylate on postoperative recovery quality after thoracoscopic lung cancer surgery: a randomized controlled study comparing with propofol

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101483
Enrollment
Unknown
Registered
2025-04-25
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Rimazolam group:In the remazolam group, 0.2-0.3 mg/kg of remazolam besylate was injected intravenously at the time of anesthesia induction, and 0.4-1 mg/kg/h of remazolam besylate was pumped intraveno
Propofol group:In the propofol group, 1-2 mg/kg of propofol was injected intravenously at the time of induction of anesthesia, and 4-10 mg/kg/h of propofol was continuously pumped during the operation

Sponsors

Jining No1 People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adult patients undergoing thoracoscopic surgery for the first time due to primary lung cancer; American Society of Anesthesiologists (ASA) physical status classification I–III, with a body mass index (BMI) of 18–30 kg/m^2.

Exclusion criteria

Exclusion criteria: Patients with significant preoperative respiratory or circulatory dysfunction; patients with hepatic or renal insufficiency (defined as AST or ALT >=1.5 times the upper limit of normal, or Cr >=1.5 times the upper limit of normal); patients with uncontrolled or poorly controlled hypertension (defined as MAP >120 mmHg); patients with a history of alcoholism or addiction to opioids or benzodiazepines, where alcoholism is defined as an average daily alcohol intake exceeding 2 units (1 unit = 360 ml of beer or 45 ml of spirits or 150 ml of 40% wine); patients who are unable to communicate verbally due to deafness, aphasia, or severe psychiatric disorders; patients with allergic constitution or known allergies to the drugs or excipients specified in the study protocol; patients whose initial intubation attempt is unsuccessful; and other situations deemed by the investigators as unsuitable for participation in the study.

Design outcomes

Primary

MeasureTime frame
Quality of Recovery Scales;

Secondary

MeasureTime frame
Hemodynamic changes;Incidence of adverse cardiovascular events and cumulative dosage of vasoactive drugs;Postoperative awakening time, extubation time, post-anesthesia care unit length of stay;Intraoperative awareness and postoperative delirium;

Countries

China

Contacts

Public ContactWenzhu Wang

Jining No1 People's Hospital

wwz7444@126.com+86 158 9878 8836

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026